Press Release: Poseida Therapeutics, Inc. Announces Agreement to Be Acquired by Roche Holdings, Inc.
Poseida Therapeutics Cut to Market Perform From Outperform by William Blair
Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com
Poseida Therapeutics Up Nearly 225%, On Pace For Record High Close -- Data Talk
H.C. Wainwright Downgrades Poseida Therapeutics(PSTX.US) to Hold Rating, Cuts Target Price to $9
Shareholder Alert: Ademi LLP Investigates Whether Poseida Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
